Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) delta variant of concern breakthrough infections: Are vaccines failing us?
作者信息
Nowroozi Ali, Rezaei Nima
机构信息
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
出版信息
Infect Control Hosp Epidemiol. 2022 Nov;43(11):1754-1755. doi: 10.1017/ice.2021.363. Epub 2021 Aug 6.
Abstract
摘要
相似文献
1
Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) delta variant of concern breakthrough infections: Are vaccines failing us?严重急性呼吸综合征冠状病毒2（SARS-CoV-2）德尔塔变异株引起的突破性感染：疫苗辜负我们了吗？
Infect Control Hosp Epidemiol. 2022 Nov;43(11):1754-1755. doi: 10.1017/ice.2021.363. Epub 2021 Aug 6.
2
SARS-CoV-2 Breakthrough Infections among US Embassy Staff Members, Uganda, May-June 2021.2021 年 5 月至 6 月期间，美国驻乌干达大使馆工作人员中出现的 SARS-CoV-2 突破感染。
Emerg Infect Dis. 2022 Jun;28(6):1279-1280. doi: 10.3201/eid2806.220427. Epub 2022 Apr 26.
3
Animal models for studying coronavirus infections and developing antiviral agents and vaccines.用于研究冠状病毒感染和开发抗病毒药物和疫苗的动物模型。
Antiviral Res. 2022 Jul;203:105345. doi: 10.1016/j.antiviral.2022.105345. Epub 2022 May 21.
4
Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines.接种严重急性呼吸综合征冠状病毒 2 载体疫苗和基于 mRNA 的疫苗后，一家三级保健医院工作人员的疫苗接种后感染。
Clin Microbiol Infect. 2022 Apr;28(4):596-601. doi: 10.1016/j.cmi.2021.11.023. Epub 2021 Dec 13.
5
Vaccines based on virus-like nano-particles for use against Middle East Respiratory Syndrome (MERS) coronavirus.基于病毒样纳米颗粒的疫苗，用于预防中东呼吸综合征（MERS）冠状病毒。
Vaccine. 2020 Aug 10;38(36):5742-5746. doi: 10.1016/j.vaccine.2020.07.003. Epub 2020 Jul 11.
6
Duration of viral shedding and culture positivity with postvaccination SARS-CoV-2 delta variant infections.接种疫苗后感染 SARS-CoV-2 德尔塔变异株的病毒脱落和培养阳性持续时间。
JCI Insight. 2022 Jan 25;7(2):e155483. doi: 10.1172/jci.insight.155483.
7
Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.微针阵列递呈的重组冠状病毒疫苗：免疫原性和快速转化开发。
EBioMedicine. 2020 May;55:102743. doi: 10.1016/j.ebiom.2020.102743. Epub 2020 Apr 2.
8
Vaccination remains the first choice to control the spread of delta and other variants of severe acute respiratory coronavirus virus 2 (SARS-CoV-2).接种疫苗仍然是控制新冠病毒（SARS-CoV-2）德尔塔及其他变异毒株传播的首要选择。
Infect Control Hosp Epidemiol. 2022 Nov;43(11):1749-1750. doi: 10.1017/ice.2021.364. Epub 2021 Aug 6.
9
COVID-19: Coronavirus Vaccine Development Updates.COVID-19：冠状病毒疫苗研发进展。
Front Immunol. 2020 Dec 23;11:602256. doi: 10.3389/fimmu.2020.602256. eCollection 2020.
10
[Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].[2019冠状病毒病及严重急性呼吸综合征冠状病毒2的诊断、治疗、控制与预防：回归未来]
Sheng Wu Gong Cheng Xue Bao. 2020 Apr 25;36(4):571-592. doi: 10.13345/j.cjb.200115.
引用本文的文献
1
Delta Variant: The New Challenge of COVID-19 Pandemic, an Overview of Epidemiological, Clinical, and Immune Characteristics.德尔塔变异株：新冠疫情的新挑战，流行病学、临床及免疫特征概述
Acta Biomed. 2022 Mar 14;93(1):e2022179. doi: 10.23750/abm.v93i1.12210.
2
Impact of the Double Mutants on Spike Protein of SARS-CoV-2 B.1.617 Lineage on the Human ACE2 Receptor Binding: A Structural Insight.关于 SARS-CoV-2 B.1.617 谱系的双突变体对人类 ACE2 受体结合的影响：结构见解。
Viruses. 2021 Nov 17;13(11):2295. doi: 10.3390/v13112295.
3
The global transmission of new coronavirus variants.新型冠状病毒变体的全球传播。
Environ Res. 2022 Apr 15;206:112240. doi: 10.1016/j.envres.2021.112240. Epub 2021 Oct 22.
本文引用的文献
1
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. Reply.新冠病毒疫苗对B.1.617.2（德尔塔）变异株的有效性。回复
N Engl J Med. 2021 Dec 16;385(25):e92. doi: 10.1056/NEJMc2113090. Epub 2021 Nov 10.
2
SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination.SARS-CoV-2 变体 B.1.617 对巴美洛单抗具有耐药性，并能逃避由感染和接种疫苗引起的抗体。
Cell Rep. 2021 Jul 20;36(3):109415. doi: 10.1016/j.celrep.2021.109415. Epub 2021 Jun 29.
3
Efficacy and Safety of COVID-19 Vaccines in Phase III Trials: A Meta-Analysis.新冠病毒疫苗Ⅲ期试验的疗效与安全性：一项荟萃分析
Vaccines (Basel). 2021 Jun 1;9(6):582. doi: 10.3390/vaccines9060582.
4
SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness.苏格兰的新冠病毒德尔塔变异株：人口统计学、住院风险及疫苗有效性
Lancet. 2021 Jun 26;397(10293):2461-2462. doi: 10.1016/S0140-6736(21)01358-1. Epub 2021 Jun 14.
Zotero 插件